---
document_datetime: 2025-06-04 11:47:58
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/beqvez-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: beqvez-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 0.9553998
conversion_datetime: 2025-12-28 14:43:38.861657
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number Scope                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                      |
|-------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 1 year / EMA/R/0000247045 - Renewal - Accepted Renewal of marketing authorisation Medicinal | 25/04/2025                          | N/A                                         | SmPC, Annex II and PL            | The CAT and CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the |

BEQVEZ Procedural steps taken and scientific information after the authorisation* *Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) . Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->